Zions Bancorporation N.A. Grows Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Zions Bancorporation N.A. increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 115,725 shares of the biopharmaceutical company’s stock after buying an additional 114 shares during the quarter. Gilead Sciences accounts for about 0.7% of Zions Bancorporation N.A.’s investment portfolio, making the stock its 18th largest position. Zions Bancorporation N.A.’s holdings in Gilead Sciences were worth $10,690,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in GILD. HHM Wealth Advisors LLC increased its position in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences during the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC lifted its holdings in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $106.74 on Tuesday. The business’s 50 day moving average price is $104.01 and its 200-day moving average price is $94.15. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a market cap of $132.93 billion, a P/E ratio of 288.49, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a $0.79 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.96%. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio is 854.05%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on GILD shares. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Bank of America increased their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Oppenheimer boosted their price objective on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 4th. Morgan Stanley increased their target price on Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 11th. Finally, Royal Bank of Canada lifted their target price on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $104.52.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 302,785 shares of company stock valued at $30,503,250 over the last 90 days. Insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.